Zentalis Pharmaceuticals, Inc.
ZNTL
$1.77
-$0.04-2.21%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 40.56M | 40.56M | 40.56M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.56M | 40.56M | 40.56M | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 40.56M | 40.56M | 40.56M | -- | -- |
| SG&A Expenses | 63.48M | 64.82M | 63.72M | 64.35M | 59.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 249.83M | 261.11M | 254.31M | 253.94M | 237.77M |
| Operating Income | -209.27M | -220.55M | -213.75M | -253.94M | -237.77M |
| Income Before Tax | -179.09M | -194.41M | -219.57M | -292.91M | -287.18M |
| Income Tax Expenses | 247.00K | 305.00K | -566.00K | -601.00K | -826.00K |
| Earnings from Continuing Operations | -179.33 | -194.72 | -219.00 | -292.31 | -286.35 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 50.00K | 62.00K | 99.00K | 114.00K | 105.00K |
| Net Income | -179.28M | -194.65M | -218.90M | -292.19M | -286.25M |
| EBIT | -209.27M | -220.55M | -213.75M | -253.94M | -237.77M |
| EBITDA | -207.96M | -219.22M | -212.40M | -252.55M | -236.36M |
| EPS Basic | -2.53 | -2.75 | -3.36 | -4.56 | -4.65 |
| Normalized Basic EPS | -1.49 | -1.63 | -1.75 | -2.51 | -2.49 |
| EPS Diluted | -2.53 | -2.75 | -3.36 | -4.57 | -4.65 |
| Normalized Diluted EPS | -1.49 | -1.63 | -1.75 | -2.51 | -2.49 |
| Average Basic Shares Outstanding | 283.88M | 283.38M | 273.13M | 261.51M | 248.81M |
| Average Diluted Shares Outstanding | 284.18M | 283.68M | 273.43M | 261.51M | 248.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
